Details for New Drug Application (NDA): 011721
✉ Email this page to a colleague
NDA 011721 describes NEPTAZANE, which is a drug marketed by Lederle and is included in one NDA. Additional details are available on the NEPTAZANE profile page.
The generic ingredient in NEPTAZANE is methazolamide. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the methazolamide profile page.
The generic ingredient in NEPTAZANE is methazolamide. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the methazolamide profile page.
Summary for 011721
| Tradename: | NEPTAZANE |
| Applicant: | Lederle |
| Ingredient: | methazolamide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 011721
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 25, 1991 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
